MA50145A - Composés inhibiteurs de vmat2 et compositions de ceux-ci - Google Patents

Composés inhibiteurs de vmat2 et compositions de ceux-ci

Info

Publication number
MA50145A
MA50145A MA050145A MA50145A MA50145A MA 50145 A MA50145 A MA 50145A MA 050145 A MA050145 A MA 050145A MA 50145 A MA50145 A MA 50145A MA 50145 A MA50145 A MA 50145A
Authority
MA
Morocco
Prior art keywords
compositions
inhibitor compounds
vmat2 inhibitor
vmat2
compounds
Prior art date
Application number
MA050145A
Other languages
English (en)
Inventor
Shawn Branum
Jeffrey C Culhane
Nicole Harriott
Donald Hettinger
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MA50145A publication Critical patent/MA50145A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA050145A 2017-04-19 2018-04-17 Composés inhibiteurs de vmat2 et compositions de ceux-ci MA50145A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US201862652837P 2018-04-04 2018-04-04

Publications (1)

Publication Number Publication Date
MA50145A true MA50145A (fr) 2020-07-29

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050145A MA50145A (fr) 2017-04-19 2018-04-17 Composés inhibiteurs de vmat2 et compositions de ceux-ci

Country Status (17)

Country Link
US (1) US11040970B2 (fr)
EP (1) EP3612532B1 (fr)
JP (1) JP7170662B2 (fr)
KR (1) KR20190140968A (fr)
CN (1) CN110770236B (fr)
AU (1) AU2018254429A1 (fr)
BR (1) BR112019021853A2 (fr)
CA (1) CA3060251A1 (fr)
CL (1) CL2019002919A1 (fr)
CO (1) CO2019011604A2 (fr)
ES (1) ES2971230T3 (fr)
JO (1) JOP20190239A1 (fr)
MA (1) MA50145A (fr)
MX (1) MX2019012336A (fr)
PE (1) PE20191784A1 (fr)
TW (1) TW201841913A (fr)
WO (1) WO2018195121A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199695A (en) 2017-01-27 2023-11-18 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
DK3684333T3 (da) 2017-09-21 2025-05-12 Neurocrine Biosciences Inc Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
MX2020013004A (es) * 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
WO2020086765A1 (fr) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Procédés de préparation d'un inhibiteur de vmat2
EP4037773A1 (fr) 2019-09-30 2022-08-10 Incyte Corporation Composés pyrido[3,2-d]pyrimidine en tant qu'immunomodulateurs
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
AR125188A1 (es) 2021-03-22 2023-06-21 Neurocrine Biosciences Inc Inhibidores del vmat2 y métodos de uso
WO2022232380A1 (fr) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Méthodes de préparation d'un inhibiteur de vmat2
US20250064990A1 (en) 2021-08-20 2025-02-27 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors
WO2026050236A1 (fr) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Agoniste du récepteur muscarinique en combinaison avec un inhibiteur du transporteur vésiculaire de la monoamine 2, destiné à être utilisé dans le traitement d'un trouble neurologique ou psychiatrique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2004251829B2 (en) 2003-06-20 2009-12-17 F. Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as DPP-IV inhibitors
CA2575979A1 (fr) 2004-08-13 2006-02-23 Omeros Corporation Nouveaux ligands de recepteur de serotonine et leurs utilisations
EP2081929B1 (fr) * 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Composés 3-isobutyl-9, 10-diméthoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol substitués et procédés associés
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9012471B2 (en) 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
EP3345905B1 (fr) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Dérivés deutérés de benzoquinolizine en tant qu'inhibiteurs du transporteur de monoamine vésiculaire 2
WO2011075699A2 (fr) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Composés pour le traitement des troubles médiés par le récepteur métabotropique 5 du glutamate, et leurs méthodes d'utilisation
CN102285984B (zh) 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
EP2835372B1 (fr) 2012-09-19 2016-05-04 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Dérivé de thiophène[2,3-d]pyrimidine et son procédé de préparation et d'utilisation
WO2015120317A1 (fr) 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Compositions pharmaceutiques comprenant un médicament antipsychotique et un inhibiteur de vmat2 et utilisations de celles-ci
CN107438606B (zh) 2015-02-06 2020-09-18 纽罗克里生物科学有限公司 [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1

Also Published As

Publication number Publication date
JP2020517607A (ja) 2020-06-18
WO2018195121A1 (fr) 2018-10-25
PE20191784A1 (es) 2019-12-24
CL2019002919A1 (es) 2020-01-17
CN110770236A (zh) 2020-02-07
CA3060251A1 (fr) 2018-10-25
KR20190140968A (ko) 2019-12-20
EP3612532B1 (fr) 2023-12-13
MX2019012336A (es) 2020-07-14
EP3612532A1 (fr) 2020-02-26
JP7170662B2 (ja) 2022-11-14
CN110770236B (zh) 2023-03-24
AU2018254429A1 (en) 2019-11-07
US11040970B2 (en) 2021-06-22
TW201841913A (zh) 2018-12-01
US20200131173A1 (en) 2020-04-30
EP3612532C0 (fr) 2023-12-13
JOP20190239A1 (ar) 2019-10-09
BR112019021853A2 (pt) 2020-05-26
CO2019011604A2 (es) 2019-10-31
ES2971230T3 (es) 2024-06-04

Similar Documents

Publication Publication Date Title
MA50145A (fr) Composés inhibiteurs de vmat2 et compositions de ceux-ci
EP3897522A4 (fr) Compositions de microcapsules
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
IL263586B (en) Inhibitors of the menin-mll interaction
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
EP3700934A4 (fr) Composés et utilisations de ces composés
MA52896A (fr) Composés inhibiteurs de vmat2, compositions et méthodes associées
EP3681499A4 (fr) Composés utilisés comme inhibiteurs de ras et leur utilisation
EP3317241A4 (fr) Composés inhibiteurs thérapeutiques
DK3143026T3 (da) Forbindelser og sammensætninger til induktion af chondrogenese
EP3842425A4 (fr) Nouvel inhibiteur de dérivé de quinoléine
MA54143A (fr) Compositions et méthodes
PT3240767T (pt) Composições microencapsuladas de inibidor da nitrificação
EP3908319A4 (fr) Composés inhibiteurs de métalloenzyme
EP3556758A4 (fr) Inhibiteur de cdk4/6
EP3810118A4 (fr) Formulations de tegavivint et composés apparentés
EP3917910A4 (fr) Composés et compositions thérapeutiques
PL4073164T3 (pl) Związki trójamidowe i kompozycje je zawierające
EP3310794A4 (fr) Synthèse et application de composés de formation de microbulles
IL264445A (en) Compounds and compositions and uses thereof
DK3678644T3 (da) Formuleringer af copanlisib
EP3661505A4 (fr) Benzothiazoles et composés connexes